FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145780557> ?p ?o ?g. }

• W2145780557 endingPage "1818" @default.
• W2145780557 startingPage "1810" @default.
• W2145780557 abstract "BackgroundThe objective of this phase I trial was to determine the maximally tolerated doses of the combination of docetaxel, epirubicin and cyclophosphamide.Patients and methodsPatients with advanced cancer, World Health Organization (WHO) performance status 0 to 2, who had received up to one prior chemotherapy regimen were treated with docetaxel, epirubicin and cyclophosphamide repeated every 21 days. The cyclophosphamide dose was fixed at 600 mg/m2 and the dose levels studied were: docetaxel/epirubicin; 60/60, 75/60, 75/75, 75/90, 85/90 and 85/105 mg/m2. There was provision for the addition of prophylactic ciprofloxacin and granulocyte colony-stimulating factor (G-CSF) in separate steps if dose-limiting toxicity (DLT) was neutropenia related.ResultsForty-three patients were entered and all were assessable for toxicity. Dose-limiting toxicity, predominantly febrile neutropenia, was surprisingly seen at the first dose level. The addition of prophylactic ciprofloxacin did not permit dose escalation, but dose escalation was possible with the addition of G-CSF. The highest administered dose level with G-CSF was docetaxel 85 mg/m2 and epirubicin 105 mg/m2 with DLTs in five of six patients. Treatment was well tolerated in 10 patients treated at the recommended dose level (85/90) with only one patient experiencing DLT. Responses were seen in a range of malignancies including breast and anaplastic thyroid cancers. No significant pharmacokinetic interaction was observed, but a transient increase in epirubicinol plasma concentration occurred during and after docetaxel infusion.ConclusionsThe recommended dose level of docetaxel 85 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 with G-CSF support has a favorable toxicity profile and is suitable for further investigation in phase II and III trials." @default.
• W2145780557 created "2016-06-24" @default.
• W2145780557 creator A5008173055 @default.
• W2145780557 creator A5018410675 @default.
• W2145780557 creator A5046335734 @default.
• W2145780557 creator A5060114622 @default.
• W2145780557 creator A5060469120 @default.
• W2145780557 creator A5066627624 @default.
• W2145780557 creator A5074842604 @default.
• W2145780557 creator A5079833339 @default.
• W2145780557 date "2002-11-01" @default.
• W2145780557 modified "2023-10-07" @default.
• W2145780557 title "Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics" @default.
• W2145780557 cites W1826360242 @default.
• W2145780557 cites W1837236202 @default.
• W2145780557 cites W1846747462 @default.
• W2145780557 cites W1848579801 @default.
• W2145780557 cites W1863320839 @default.
• W2145780557 cites W1949811104 @default.
• W2145780557 cites W1955744924 @default.
• W2145780557 cites W1960713055 @default.
• W2145780557 cites W1997378356 @default.
• W2145780557 cites W2011326694 @default.
• W2145780557 cites W2029510225 @default.
• W2145780557 cites W2031626526 @default.
• W2145780557 cites W2060703328 @default.
• W2145780557 cites W2102937068 @default.
• W2145780557 cites W2103999755 @default.
• W2145780557 cites W2112443004 @default.
• W2145780557 cites W2122468945 @default.
• W2145780557 cites W2136215569 @default.
• W2145780557 cites W2141056749 @default.
• W2145780557 cites W2145081663 @default.
• W2145780557 cites W2155199802 @default.
• W2145780557 cites W2175322882 @default.
• W2145780557 cites W2183288147 @default.
• W2145780557 cites W2203687533 @default.
• W2145780557 cites W2228702773 @default.
• W2145780557 cites W2282932528 @default.
• W2145780557 cites W4244497714 @default.
• W2145780557 doi "https://doi.org/10.1093/annonc/mdf305" @default.
• W2145780557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12419756" @default.
• W2145780557 hasPublicationYear "2002" @default.
• W2145780557 type Work @default.
• W2145780557 sameAs 2145780557 @default.
• W2145780557 citedByCount "11" @default.
• W2145780557 crossrefType "journal-article" @default.
• W2145780557 hasAuthorship W2145780557A5008173055 @default.
• W2145780557 hasAuthorship W2145780557A5018410675 @default.
• W2145780557 hasAuthorship W2145780557A5046335734 @default.
• W2145780557 hasAuthorship W2145780557A5060114622 @default.
• W2145780557 hasAuthorship W2145780557A5060469120 @default.
• W2145780557 hasAuthorship W2145780557A5066627624 @default.
• W2145780557 hasAuthorship W2145780557A5074842604 @default.
• W2145780557 hasAuthorship W2145780557A5079833339 @default.
• W2145780557 hasBestOaLocation W21457805571 @default.
• W2145780557 hasConcept C112705442 @default.
• W2145780557 hasConcept C126322002 @default.
• W2145780557 hasConcept C143998085 @default.
• W2145780557 hasConcept C2776694085 @default.
• W2145780557 hasConcept C2776755627 @default.
• W2145780557 hasConcept C2777063308 @default.
• W2145780557 hasConcept C2778850193 @default.
• W2145780557 hasConcept C2780835546 @default.
• W2145780557 hasConcept C2781190966 @default.
• W2145780557 hasConcept C2781413609 @default.
• W2145780557 hasConcept C29730261 @default.
• W2145780557 hasConcept C71924100 @default.
• W2145780557 hasConcept C90924648 @default.
• W2145780557 hasConcept C98274493 @default.
• W2145780557 hasConceptScore W2145780557C112705442 @default.
• W2145780557 hasConceptScore W2145780557C126322002 @default.
• W2145780557 hasConceptScore W2145780557C143998085 @default.
• W2145780557 hasConceptScore W2145780557C2776694085 @default.
• W2145780557 hasConceptScore W2145780557C2776755627 @default.
• W2145780557 hasConceptScore W2145780557C2777063308 @default.
• W2145780557 hasConceptScore W2145780557C2778850193 @default.
• W2145780557 hasConceptScore W2145780557C2780835546 @default.
• W2145780557 hasConceptScore W2145780557C2781190966 @default.
• W2145780557 hasConceptScore W2145780557C2781413609 @default.
• W2145780557 hasConceptScore W2145780557C29730261 @default.
• W2145780557 hasConceptScore W2145780557C71924100 @default.
• W2145780557 hasConceptScore W2145780557C90924648 @default.
• W2145780557 hasConceptScore W2145780557C98274493 @default.
• W2145780557 hasIssue "11" @default.
• W2145780557 hasLocation W21457805571 @default.
• W2145780557 hasLocation W21457805572 @default.
• W2145780557 hasOpenAccess W2145780557 @default.
• W2145780557 hasPrimaryLocation W21457805571 @default.
• W2145780557 hasRelatedWork W1998091677 @default.
• W2145780557 hasRelatedWork W2001597364 @default.
• W2145780557 hasRelatedWork W2017239577 @default.
• W2145780557 hasRelatedWork W2058098342 @default.
• W2145780557 hasRelatedWork W2328084067 @default.
• W2145780557 hasRelatedWork W2385399138 @default.
• W2145780557 hasRelatedWork W2397786201 @default.
• W2145780557 hasRelatedWork W2418847095 @default.
• W2145780557 hasRelatedWork W3031289629 @default.

• next